Loader

Pathways

PathWhiz ID Pathway Meta Data

PW123577

Pw123577 View Pathway
signaling

aha

Homo sapiens

PW122139

Pw122139 View Pathway
signaling

Agrin in Postsynaptic Differentiation

Homo sapiens
Agrin and acetylcholine act in parallel to shape the postsynaptic apparatus, and skeletal neuromuscular junction development depends critically on the interactions between these factors. In addition to its role in clustering acetylcholine, which has been demonstrated in vitro, agrin also acts to antagonize the effect of acetylcholine receptors. The antideclustering effects of agrin are physiologically crucial, agrin's antideclustering effects in vitro require its z-exon which has been shown to be required for postsynaptic differentiation in vivo.

PW128330

Pw128330 View Pathway
drug action

Agomelatine Serotonin Antagonist Action Pathway

Homo sapiens
Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors and promotes dopamine and norepinephrine release. Agomelatine is indicated to treat major depressive episodes in adults. It is an atypical antidepressant.

PW176372

Pw176372 View Pathway
metabolic

Agomelatine Predicted Metabolism Pathway

Homo sapiens
Metabolites of Agomelatine are predicted with biotransformer.

PW145720

Pw145720 View Pathway
drug action

Agomelatine Drug Metabolism Action Pathway

Homo sapiens

PW012844

Pw012844 View Pathway
metabolic

Agnieszka Bielska 1471277183

Homo sapiens

PW002692

Pw002692 View Pathway
signaling

Agnieszka Bielska

Homo sapiens

PW145889

Pw145889 View Pathway
drug action

Afatinib Drug Metabolism Action Pathway

Homo sapiens

PW128495

Pw128495 View Pathway
drug action

Afatinib Action Pathway

Homo sapiens
Afatinib is a tyrosine kinase inhibitor used as an antineoplastic agent for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy. Afatinib binds the phosphorylation domain of the epidermal growth factor receptor. This inhibits the activation of this receptor, thus the cascading signaling pathways, through RAS, can't happen. As a result, this drug provokes the inhibition of cell (cancer) proliferation. Also, Afatinib inhibits the receptor tyrosine-protein kinase erbB-2 and erbB-4. Those receptors usually send a signal to the cell to survive (through the transcription of many proteins and with the help of P13K, AKT, and mTOR). The inhibition of those receptors results in the inhibition of the survival of the cell (death/apoptosis). This drug is administered as an oral tablet.

PW145615

Pw145615 View Pathway
drug action

Afamelanotide Drug Metabolism Action Pathway

Homo sapiens